Carcinogenesis, Vol 18, 1723-1727, Copyright © 1997 by Oxford University Press
H Inano, K Suzuki, M Onoda and K Wakabayashi
Pregnant Wistar-MS rats received whole body irradiation with 2.6 Gy
gamma-rays from a 60Co source at day 20 of pregnancy. Control rats were fed
a basal diet and were implanted with a diethylstilbestrol (DES) pellet at
30 days after weaning. In the experimental group, rats were fed a diet
containing simvastatin immediately after weaning and received a DES pellet
at 30 days after weaning. A high incidence of total mammary tumours was
observed in the rats fed the control diet and treated with DES for 1 year.
The administration of dietary simvastatin together with DES treatment
significantly decreased the incidence of mammary tumours. The development
of adenocarcinoma in the control rats was significantly higher than that in
the rats fed the simvastatin diet. After the administration of simvastatin
to the experimental group for 1 year, the serum estradiol-17beta
concentration in these rats was markedly reduced, but that of prolactin was
not. No significant difference was seen in the development of the mammary
glands between rats fed the control diet and those fed the simvastatin diet
by whole mount observations. Simvastatin feeding produced an increased
development of ER- PgR- tumours and a reduced incidence of ER+ PgR+
tumours. These findings suggest that simvastatin has a potent preventive
activity during the DES-dependent promotion/progression phase of
radiation-induced mammary tumorigenesis.
ARTICLES
Anti-carcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of rats
The First Research Group, National Institute of Radiological Sciences, Chiba-shi, Japan.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. M. Boudreau, O. Yu, D. L. Miglioretti, D. S.M. Buist, S. R. Heckbert, and J. R. Daling Statin Use and Breast Cancer Risk in a Large Population-Based Setting Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 416 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Vogel Can Statin Therapy Reduce the Risk of Breast Cancer? J. Clin. Oncol., December 1, 2005; 23(34): 8553 - 8555. [Full Text] [PDF]
|
|
|
|
|
|
S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies J. Clin. Oncol., December 1, 2005; 23(34): 8606 - 8612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Duncan, A. El-Sohemy, and M. C. Archer Statins and Cancer Development Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1897 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-A. Shibata, Y. Ito, J. Morimoto, and Y. Otsuki Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism Carcinogenesis, October 1, 2004; 25(10): 1887 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-A. Shibata, C. Kavanaugh, E. Shibata, H. Abe, P. Nguyen, Y. Otsuki, J. B. Trepel, and J. E. Green Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models Carcinogenesis, March 1, 2003; 24(3): 453 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. W. Chan, A. M. Oza, and L. L. Siu The Statins as Anticancer Agents Clin. Cancer Res., January 1, 2003; 9(1): 10 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. El-Sohemy and M. C. Archer Inhibition of N-methyl-N-nitrosourea- and 7,12-dimethylbenz[a] anthracene-induced rat mammary tumorigenesis by dietary cholesterol is independent of Ha-ras mutations Carcinogenesis, April 1, 2000; 21(4): 827 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Inano, M. Onoda, N. Inafuku, M. Kubota, Y. Kamada, T. Osawa, H. Kobayashi, and K. Wakabayashi Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with {gamma}-rays Carcinogenesis, June 1, 1999; 20(6): 1011 - 1018. [Abstract] [Full Text] [PDF]
|
|